思林傑(688115.SH):公司與華為合作的是工業無線網絡應用相關的產品
格隆匯10月11日丨思林傑(688115.SH)接受特定對象調研時表示,公司與華為合作的是工業無線網絡應用相關的產品。公司在生產測試及控制的場景中,接觸到工業網絡的應用需求。這些場景內需要對相關生產及測試設備的數據採集與回傳,還可能需要對遠端的設備進行控制。公司針對這些場景需求打造相應的工業網絡解決方案。其中配合華為的無線基礎設施方案,提供了工業級的 WiFi6 CPE 產品,助力製造業打造數字化產線和工廠智能化建設。目前該產品的合作處於起步階段,公司將保持以客户為中心,切實做好產品和技術服務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.